Suppr超能文献

微粉化棕榈酰乙醇胺(microPEA)的安全性:无毒性和遗传毒性潜力。

Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential.

作者信息

Nestmann Earle R

机构信息

Health Science Consultants Inc. Mississauga Ontario L5N 7S2 Canada.

出版信息

Food Sci Nutr. 2016 Jun 15;5(2):292-309. doi: 10.1002/fsn3.392. eCollection 2017 Mar.

Abstract

Palmitoylethanolamide (PEA) is a natural fatty acid amide found in a variety of foods, which was initially identified in egg yolk. MicroPEA of defined particle size (0.5-10 m) was evaluated for mutagenicity in for clastogenicity/aneuploidy in cultured human lymphocytes, and for acute and subchronic rodent toxicity in the rat, following standard OECD test protocols, in accordance with Good Laboratory Practice (GLP). PEA did not induce mutations in the bacterial assay using strains TA1535, TA97a, TA98, TA100, and TA102, with or without metabolic activation, in either the plate incorporation or liquid preincubation methods. Similarly, PEA did not induce genotoxic effects in human cells treated for 3 or 24 h without metabolic activation, or for 3 h with metabolic activation. PEA was found to have an LD50 greater than the limit dose of 2000 mg/kg body weight (bw), using the OECD Acute Oral Up and Down Procedure. Doses for the 90-day rat oral toxicity study were based on results from the preliminary 14-day study, that is, 250, 500, and 1000 mg/kg bw/day. The No Effect Level (NOEL) in both subchronic studies was the highest dose tested.

摘要

棕榈酰乙醇胺(PEA)是一种存在于多种食物中的天然脂肪酸酰胺,最初是在蛋黄中发现的。按照经济合作与发展组织(OECD)标准试验方案并依据良好实验室规范(GLP),对粒径确定为0.5 - 10微米的微PEA进行了如下评估:在细菌回复突变试验中检测其致突变性,在培养的人淋巴细胞中检测其染色体断裂/非整倍体诱导性,以及在大鼠中检测其急性和亚慢性毒性。在平板掺入法或液体预孵育法中,无论有无代谢活化,PEA在使用TA1535、TA97a、TA98、TA100和TA102菌株的细菌试验中均未诱导突变。同样,在无代谢活化处理3或24小时或有代谢活化处理3小时的人细胞中,PEA也未诱导遗传毒性效应。使用OECD急性经口上下法,发现PEA的半数致死剂量(LD50)大于2000毫克/千克体重的极限剂量。90天大鼠经口毒性研究的剂量基于初步14天研究的结果,即250、500和1000毫克/千克体重/天。两项亚慢性研究中的无效应水平(NOEL)均为所测试的最高剂量。

相似文献

1
Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential.
Food Sci Nutr. 2016 Jun 15;5(2):292-309. doi: 10.1002/fsn3.392. eCollection 2017 Mar.
4
The mutagenic assessment of an electronic-cigarette and reference cigarette smoke using the Ames assay in strains TA98 and TA100.
Mutat Res Genet Toxicol Environ Mutagen. 2016 Dec;812:29-38. doi: 10.1016/j.mrgentox.2016.10.005. Epub 2016 Oct 29.
5
Toxicological studies on the botanical supplement LI12542F6 containing extracts of flower heads and (mango tree) bark.
Food Sci Nutr. 2019 Jan 29;7(2):817-833. doi: 10.1002/fsn3.931. eCollection 2019 Feb.
7
Acute, subacute oral toxicity and Ames test of Py-mulin: an antibacterial drug candidate.
BMC Pharmacol Toxicol. 2022 Jan 4;23(1):2. doi: 10.1186/s40360-021-00543-5.
9
Mutagenicity and clastogenicity evaluation of metaphenoxy benzyl chloride by ames and micronucleus assays.
Drug Chem Toxicol. 2015 Apr;38(2):235-40. doi: 10.3109/01480545.2014.947424. Epub 2014 Aug 11.
10
Genotoxic evaluation of aspirin eugenol ester using the Ames test and the mouse bone marrow micronucleus assay.
Food Chem Toxicol. 2013 Dec;62:805-9. doi: 10.1016/j.fct.2013.10.010. Epub 2013 Oct 16.

引用本文的文献

3
Novel drug treatments for pain in advanced cancer and serious illness: a focus on neuropathic pain and chemotherapy-induced peripheral neuropathy.
Palliat Care Soc Pract. 2024 Jul 31;18:26323524241266603. doi: 10.1177/26323524241266603. eCollection 2024.
5
Effect of palmitoylethanolamide on degeneration of a human-derived retinal pigment epithelial cell induced by all-trans retinal.
Int J Ophthalmol. 2023 Feb 18;16(2):191-200. doi: 10.18240/ijo.2023.02.04. eCollection 2023.
6
Palmitoylethanolamide and Related ALIAmides for Small Animal Health: State of the Art.
Biomolecules. 2022 Aug 26;12(9):1186. doi: 10.3390/biom12091186.
10
Genetically-targeted photorelease of endocannabinoids enables optical control of GPR55 in pancreatic β-cells.
Chem Sci. 2021 Sep 15;12(40):13506-13512. doi: 10.1039/d1sc02527a. eCollection 2021 Oct 20.

本文引用的文献

4
Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients.
Pain Res Treat. 2014;2014:849623. doi: 10.1155/2014/849623. Epub 2014 Apr 2.
6
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.
Inflammopharmacology. 2014 Apr;22(2):79-94. doi: 10.1007/s10787-013-0191-7. Epub 2013 Nov 1.
7
Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.
Mol Neurobiol. 2013 Oct;48(2):340-52. doi: 10.1007/s12035-013-8487-6. Epub 2013 Jun 28.
8
Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis.
Pain Med. 2012 Sep;13(9):1121-30. doi: 10.1111/j.1526-4637.2012.01432.x. Epub 2012 Jul 30.
10
Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy.
CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. doi: 10.2174/187152711799219307.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验